Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 4.2% After Insider Buying Activity

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares shot up 4.2% during trading on Tuesday following insider buying activity. The stock traded as high as $27.89 and last traded at $27.30. 107,913 shares were traded during mid-day trading, a decline of 88% from the average session volume of 869,580 shares. The stock had previously closed at $26.21.

Specifically, CEO Anthony S. Marucci bought 11,500 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Citigroup started coverage on Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

The firm has a market capitalization of $1.79 billion, a P/E ratio of -10.65 and a beta of 1.60. The firm has a fifty day simple moving average of $33.29 and a two-hundred day simple moving average of $35.72.

Institutional Investors Weigh In On Celldex Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Novo Holdings A S lifted its holdings in Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after purchasing an additional 113,663 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after buying an additional 2,664,915 shares during the period. Swiss National Bank raised its holdings in Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock valued at $4,797,000 after acquiring an additional 17,300 shares during the period. Bellevue Group AG lifted its position in shares of Celldex Therapeutics by 15.7% during the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock worth $117,374,000 after acquiring an additional 380,319 shares in the last quarter. Finally, AlphaCentric Advisors LLC boosted its holdings in shares of Celldex Therapeutics by 23.4% in the second quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company’s stock worth $1,758,000 after acquiring an additional 9,000 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.